Literature DB >> 2408269

Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.

H A Liebman, S A Limentani, B C Furie, B Furie.   

Abstract

Factor IX is a vitamin K-dependent blood clotting zymogen that is functionally defective or absent in patients with hemophilia B. A method of immunoaffinity chromatography has been developed for a one-step high yield purification of factor IX directly from plasma. The technique utilizes conformation-specific antibodies that bind solely to the metal-stabilized factor IX conformer, but not to the conformer of factor IX found in the absence of metal ions. Anti-factor IX-Ca(II) antibodies were immobilized on an agarose matrix. Human plasma in the presence of 7.5 mM MgCl2 was applied to the antibody-agarose column. The factor IX that binds to these antibodies was specifically eluted by metal chelation with EDTA. This immunopurification resulted in a 10,000-fold one-step purification of the fully functional zymogen. Purified factor IX yielded a single band upon gel electrophoresis in Na-DodSO4 and had a specific activity of 120-150 units/mg. The purified factor IX was separated from other vitamin K-dependent blood clotting proteins and hepatitis virus; no activated factor IX was detected. This method has application for the large scale purification of factor IX for the treatment of hemophilia B.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2408269      PMCID: PMC397892          DOI: 10.1073/pnas.82.11.3879

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

Authors:  E W DAVIE; O D RATNOFF
Journal:  Science       Date:  1964-09-18       Impact factor: 47.728

2.  THROMBIN AND THE INTERACTION OF FACTORS 8 AND 9.

Authors:  R BIGGS; R G MACFARLANE; K W DENSON; B J ASH
Journal:  Br J Haematol       Date:  1965-05       Impact factor: 6.998

3.  Hemophilia B: characterization of genetic variants and detection of carriers.

Authors:  C K Kasper; B Osterud; J Y Minami; W Shonick; S I Rapaport
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

4.  Post-Konyne hepatitis: the ineffectiveness of screening for the hepatitis B antigen (HBAg).

Authors:  S G Sandler; C E Rath; M Wickerhauser; R Y Dodd; T J Greenwalt
Journal:  Transfusion       Date:  1973 Jul-Aug       Impact factor: 3.157

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Conformation-specific antibodies directed against the bovine prothrombin . calcium complex.

Authors:  M M Tai; B C Furie; B Furie
Journal:  J Biol Chem       Date:  1980-04-10       Impact factor: 5.157

7.  The interaction of Ca2+ with human Factor IX.

Authors:  G W Amphlett; W Kisiel; F J Castellino
Journal:  Arch Biochem Biophys       Date:  1981-05       Impact factor: 4.013

8.  Activation of human factor IX (Christmas factor).

Authors:  R G Di Scipio; K Kurachi; E W Davie
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

9.  Properties of the factor Xa binding site on human platelets.

Authors:  J P Miletich; C M Jackson; P W Majerus
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

10.  Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.

Authors:  K S Chung; D A Madar; J C Goldsmith; H S Kingdon; H R Roberts
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

View more
  9 in total

1.  Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures.

Authors:  V M Knepp; A Muchnik; S Oldmark; L Kalashnikova
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

2.  Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases.

Authors:  David T Hickman; María Pilar López-Deber; Dorin Mlaki Ndao; Alberto B Silva; Deepak Nand; Maria Pihlgren; Valérie Giriens; Rime Madani; Annie St-Pierre; Hristina Karastaneva; Luitgard Nagel-Steger; Dieter Willbold; Detlev Riesner; Claude Nicolau; Marc Baldus; Andrea Pfeifer; Andreas Muhs
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

Review 3.  Immunoaffinity chromatography.

Authors:  G W Jack
Journal:  Mol Biotechnol       Date:  1994-02       Impact factor: 2.695

4.  The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.

Authors:  H ten Cate; K A Bauer; M Levi; T S Edgington; R D Sublett; S Barzegar; B L Kass; R D Rosenberg
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

5.  Mini-review on "A novel one-step purification of mouse factor IX".

Authors:  Sumita Choudhury; William E Plautz; Cosette Zacarias; Rinku Majumder
Journal:  J Rare Dis Res Treat       Date:  2016

6.  Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.

Authors:  Ulrik H Mistarz; Susheel K Singh; Tam T T N Nguyen; Will Roeffen; Fen Yang; Casper Lissau; Søren M Madsen; Astrid Vrang; Régis W Tiendrebeogo; Ikhlaq H Kana; Robert W Sauerwein; Michael Theisen; Kasper D Rand
Journal:  Pharm Res       Date:  2017-06-23       Impact factor: 4.200

7.  Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion.

Authors:  G L Bray; A R Thompson
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

8.  Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor.

Authors:  D L Diuguid; M J Rabiet; B C Furie; H A Liebman; B Furie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

9.  Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin.

Authors:  Jianming Liu; Anna Jonebring; Jonas Hagström; Ann-Christin Nyström; Ann Lövgren
Journal:  Protein J       Date:  2014-04       Impact factor: 2.371

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.